Cyclooxygenase inhibition prevents PMA-induced increase in pulmonary vascular permeability to albumin.
In a previous study, we demonstrated that phorbol myristate acetate-(PMA) induced injury in isolated blood-perfused rabbit lungs was characterized by increased pulmonary vascular resistance (PVR) and permeability to water as measured by fluid filtration coefficient (Kf). The Kf increase was prevented by pretreatment with three cyclooxygenase inhibitors, indomethacin, ibuprofen, and meclofenamate. Other studies have shown that PMA causes a decrease in pulmonary vascular surface area, probably due to the increase in arterial resistance. Measurement of Kf requires increased microvascular pressure, and therefore Kf estimates the permeability of the entire vascular bed. Thus the permeability of the flowing vessels may be overestimated by Kf. In this study, we chose to investigate the effect of PMA on vascular permeability to protein by measuring albumin leak. Because this measurement does not require a hydraulic stress, it is more likely to reflect the permeability of flowing vessels. PMA administration (5 x 10(-8) M) caused significant increases in both PVR and 125I-labeled bovine serum albumin leak. Cyclooxygenase inhibition with indomethacin, ibuprofen, or meclofenamate prevented the PMA-induced increase in albumin leak without affecting the PVR increase. These results suggest that cyclooxygenase-mediated products of arachidonic acid mediate the PMA-induced increase in vascular permeability to both water and protein.
Zanaboni
P B
PB
Department of Pharmacology, St. Louis University School of Medicine, Missouri 63104.
Bradley
J D
JD
Webster
R O
RO
Dahms
T E
TE
D000418:Albumins / Q000378:metabolism*; D000818:Animals; D001794:Blood Pressure / Q000502:physiology; D002199:Capillary Permeability / Q000187:drug effects*; D002463:Cell Membrane Permeability / Q000187:drug effects; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D007457:Iodine Radioisotopes; D008168:Lung / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D011651:Pulmonary Artery / Q000502:physiology; D011669:Pulmonary Wedge Pressure / Q000502:physiology; D011817:Rabbits; D013755:Tetradecanoylphorbol Acetate / Q000633:toxicity*; D014655:Vascular Resistance / Q000187:drug effects
D000418:Albumins; D016861:Cyclooxygenase Inhibitors; D007457:Iodine Radioisotopes; D013755:Tetradecanoylphorbol Acetate